H.I.G. Capital News
Contact:Chris Erdman MacDougall Biomedical Communications 508.647.0209 x14
NeurAxon, Inc. to Present at BMO Capital Markets 10th Annual Focus on Healthcare Conference August 5, 2010
WALTHAM, MA - July 29, 2010 - NeurAxon, Inc. is pleased to announce that Lawrence Bloch, M.D., J.D., the Company’s Chief Executive Officer, will present at the BMO Capital Markets 10th Annual Focus on Healthcare Conference taking place August 5, 2010 in New York City.
The NeurAxon presentation will be delivered on Thursday, August 5, 2010 at 11:15am Eastern Time at the Sheraton New York Hotel & Towers.
Dr. Bloch will provide an overview of NeurAxon and its portfolio of internally generated, novel, proprietary pain therapeutics including its lead candidate, NXN-188, an oral, first-in-class, selective nNOS inhibitor and 5HT agonist which is currently in Phase 2 development for the treatment of acute migraine.
About NeurAxon, Inc.
NeurAxon, Inc. (www.neuraxon.com) discovers and develops next-generation pain therapeutics focused on its first-in-class selective inhibitors of neuronal nitric oxide synthase (nNOS), an enzyme involved in modulating pain and central nervous system neuronal sensitization.